Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
Overall, the combination of IL-21 with Rituxan was well tolerated in patients with relapsed and refractory indolent lymphoma
and was associated with an ORR of 38%.
The goal of treating patients with indolent lymphomas
is to keep them disease-free and treatment-free for as long as possible.
represent 40% and MCL 3-10% of all NHL subtypes.
In contrast, patients with follicular and other indolent lymphomas
can sustain prolonged remission periods, but eventually relapse and require subsequent courses of therapy that lead to fewer and shorter remissions .
8) Unfortunately, well-defined treatment strategies in SMZL and other indolent lymphomas
have not been described.
Lymphoma Patients Being 'Hit' With Aggressive Disease : With indolent lymphomas
, there have been many new advances that provide treatment options for patients who have this type of lymphoma.
million to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber, to co-fund the completion of pre-clinical development, manufacturing, and a Phase I clinical trial for a novel fusion protein that may change the poor outcomes faced by many patients with indolent lymphomas
who do not respond to standard therapy with rituximab.